Business Wire

Introducing Starbucks Oleato™ – a Revolutionary New Coffee Ritual

22.2.2023 00:00:00 EET | Business Wire | Press release

Share

Starbucks today unveiled a transformational innovation in coffee, Oleato – a line of coffee beverages that brings together the unexpected – Starbucks arabica coffee deliciously infused with a spoonful of Partanna cold pressed, extra virgin olive oil. The result is velvety smooth, delicately sweet, and lush coffee that uplifts each cup with an extraordinary new flavor and texture. The new beverage platform which launches in Starbucks stores in Italy on Feb. 22, includes: Oleato™ Caffè Latte, Oleato™ Iced Shaken Espresso, and Oleato™ Golden Foam™ Cold Brew. The Starbucks Reserve Roastery Milan will also debut five beverages to customers on Feb. 22: Oleato™ Caffè Latte, Oleato™ Iced Cortado, Oleato™ Golden Foam™ Cold Brew, Oleato™ Deconstructed, and Oleato™ Golden Foam™ Espresso Martini. Starbucks will begin to introduce the beverages in select markets around the world, starting with Southern California in the United States this spring. Later this year, Japan, the Middle East, and the United Kingdom will launch the beverages.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230221005753/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Introducing Starbucks Oleato™ – a Revolutionary New Coffee Ritual (Photo: Business Wire)

“During my first trip to Milan in 1983, I was captivated by the sense of community, connection, and passion for coffee I found in the city’s espresso bars. It was that trip that inspired me to bring the ritual of handcrafted espresso to Starbucks and to America. Oleato represents the next revolution in coffee that brings together an alchemy of nature’s finest ingredients – Starbucks arabica coffee beans and Partanna cold pressed extra virgin olive oil,” said Howard Schultz, Starbucks interim chief executive officer. “Today I feel just as inspired as I did 40 years ago, Oleato has opened our eyes to fresh new possibilities and a transformational way to enjoy our daily coffee,” said Schultz.

Starbucks continuous search for inspiration revealed a family tradition that has existed in regions of Italy for generations - enjoying a spoonful of extra virgin olive oil each day as an uplifting ritual. This led Starbucks to Partanna, an Italian extra virgin olive oil brand with more than 100 years of tradition and dedication to farming and crafting premium extra virgin olive oil.

Oleato, The New Coffee Ritual

Partanna created a highly curated blend of extra virgin olive oil from the finest Mediterranean olives, including the high-quality Nocellara del Belice (also called Castelvetrano) olives from Partanna, Sicily. The blend was thoughtfully selected to pair perfectly with Starbucks coffee, which is then skillfully infused in the beverage to unlock a smooth and delicious experience like no other.

Starbucks Oleato beverages that will be served in Starbucks stores around the world:

  • Oleato™ Caffè Latte : Starbucks Blonde Espresso Roast, a light roast that is smooth and subtly sweet, is infused with Partanna extra virgin olive oil and steamed with creamy oatmilk to create a velvety smooth, deliciously lush latte.
  • Oleato™ Golden Foam™ Cold Brew : The inviting aroma of lush Partanna extra virgin olive oil infused cold foam cascades slowly through the dark, smooth cold brew, creating a subtle sweetness in the beverage.
  • Oleato™ Iced Shaken Espresso : This coffee-forward beverage offers layers of flavor sweetened with notes of hazelnuts, rich espresso and creamy oatmilk infused with Partanna extra virgin olive oil.

In select markets, customers will also be able to add a press – the equivalent to a spoonful – of Partanna extra virgin olive oil as a customization to select beverages. The press will then be infused (steamed, shaken, or blended) as a customization into select drinks such as espresso beverages and tea lattes. Golden Foam will also be available as a customization, which can be added as a delicious topping on both hot and cold beverages.

Designed to pair perfectly with the exquisite Starbucks Reserve coffee, the Starbucks Reserve Roastery Milan today debuted five Starbucks Reserve Oleato beverages:

  • Oleato™ Caffè Latte : Starbucks Reserve Espresso and creamy oatmilk infused with Partanna extra virgin olive oil create a velvety, luscious latte.
  • Oleato™ Iced Cortado : Starbucks Reserve Espresso, demerara syrup, and a dash of orange bitters and oatmilk is infused with Partanna extra virgin olive oil. It is then served over ice and finished with an orange peel.
  • Oleato™ Golden Foam™ Cold Brew : Starbucks Reserve Cold Brew is lightly sweetened with demerara syrup and finished with Partanna extra virgin olive oil infused cold foam, creating an inviting aroma and subtle sweetness.
  • Oleato™ Deconstructed : An ode to the Italian tradition of combining olive oil with a squeeze of lemon. This beverage pairs Starbucks Reserve Espresso and Partanna extra virgin olive oil infused with a luxurious passionfruit cold foam.
  • Oleato™ Golden Foam™ Espresso Martini : Starbucks Reserve Espresso, vodka and vanilla bean syrup topped with golden foam – a fusion of fior di latte (sweet cream) and Partanna extra virgin olive oil.

“When creating the beverages, we were inspired by the rich history and origin stories of coffee and olive oil – two of nature’s most transcendent ingredients,” said Amy Dilger, principal beverage developer for Starbucks. “Infusing Starbucks coffee with olive oil yielded a velvety smooth, rich texture, with the buttery, round flavors imparted by the olive oil perfectly pairing with the soft, chocolatey notes of the coffee.”

“One thing that’s special about Partanna’s olives is their uniquely nutty, slightly sweet flavors – think of that rich smoothness of a buttery caramel, it’s a natural complement to our coffee,” said Dilger. “Whether you enjoy Oleato hot or cold, you get this really luxurious, textural experience.”

Read more about the inspiration and creation of these beverages here.

Raising the Bar on Coffee Innovation

Italy’s romance with coffee, food and connection has served as an inspiration for the Starbucks Experience since the company’s earliest days, influencing its coffee, food, and store designs, as well as its reverence for artistry.

“The art of coffee craft, curation and creation remains core to Starbucks. Our aspiration to continue to be the world's leader in premium coffee – in both the art and the science – is as strong today as it was more than 50 years ago when Starbucks first opened its doors,” said Schultz. “Embracing our heritage, we remain dedicated to exceeding our customers’ expectations by bringing innovative experiences to savor.”

From the first Starbucks Caffè Latte served in 1984, to Pumpkin Spice Latte, Nitro Cold Brew, and the more recent Iced Shaken Espresso beverages, Starbucks continues to bring its customers innovative beverages at scale.

About Starbucks

Since 1971, Starbucks Coffee Company has been committed to ethically sourcing and roasting high-quality arabica coffee. Today, with nearly 36,000 stores worldwide, the company is the premier roaster and retailer of specialty coffee in the world. Through our unwavering commitment to excellence and our guiding principles, we bring the unique Starbucks Experience to life for every customer through every cup. To share in the experience, please visit us in our stores or online at stories.starbucks.com or starbucks.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Email: press@starbucks.com
Hotline: 206-318-7100

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye